Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

212 results about "Vascular dilatation" patented technology

When blood vessels dilate, the flow of blood is increased due to a decrease in vascular resistance. Therefore, dilation of arterial blood vessels (mainly the arterioles) decreases blood pressure.

Intra-aortic renal delivery catheter

InactiveUS7063679B2Significant mixingIncreased taper pitchGuide needlesStentsPuncture WoundBoth kidneys
A renal flow system and method direct fluid into renal arteries from a location within the aorta. A renal flow assembly has a tapered tube that is adjustable between a radially collapsed condition for delivery to the location through a delivery sheath and a radially expanded condition that divides aortic flow into exterior and interior paths. The tube's wall is made from a sheet of flexible material, such as PTFE or ePTFE. Two, nickel-titanium rings radially support the tube's ends and are connected by a longitudinal spine support. A fluid delivery assembly injects drug to flow along the exterior flow path and the tubular wall directs the agent into the renal artery ostium. The tube's taper has localized shape for circumferential agent mixing to infuse both kidneys' renals. The flow assembly allows an interventional device, e.g. delivery catheter, to advance across the location while directing blood into the renals and perfusing downstream circulation. The renal flow assembly and distal device are used within a common guide sheath through a single puncture wound. Vasodilators, antioxidants, or diuretics are delivered to the kidneys to treat / prevent RCN, CHF, or ARF.
Owner:ANGIODYNAMICS INC

Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney by infusion of a vasodilator

A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.
Owner:GAMBRO LUNDIA AB

Composition for collecting and preserving placental stem cells and methods of using the composition

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.
Owner:CELULARITY INC

Supplemented and unsupplemented tissue sealants, methods of their production and use

This invention provides a fibrin sealant bandage, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, anti-inflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and / or using the unsupplemented or supplemented fibrin sealant bandage.
Owner:AMERICAN NAT RED CROSS

Supplemented and unsupplemented tissue sealants, methods of their production and use

This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds, antibody, antimicrobial compositions, analgesics, anticoagulants, antiproliferatives, antiinflammatory compounds, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Also disclosed are methods of preparing and / or using the unsupplemented or supplemented fibrin sealant dressing.
Owner:AMERICAN NAT RED CROSS

Formulations and method for treating baldness

InactiveUS20060067905A1Lower Level RequirementsSlow, prevent, or even reverse hair lossCosmetic preparationsHair removalPersonal careApigenin
The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a personal care, cosmetic, and / or dermopharmaceutical composition comprising oleanolic acid, apigenin, biotinyl-GHK, and at least one additional ingredient, and 4) a method for treating hair loss comprising the administration of oleanolic acid, apigenin, and biotinyl-GHK.
Owner:SEDERMA SA

Assessment of vascular dilatation

ActiveUS20050070805A1Faster measurement procedureCatheterSensorsSystoleCardiac cycle
A method and apparatus of assessment of relative changes in the cross sectional area of a limb artery. The method includes applying to the artery an external pressure, which causes the cross-sectional area of the artery to change between systole and diastole much more than if the pressure is not applied, determining, over one or more cardiac cycles, a baseline value for a parameter related to the cross-sectional area of the artery, while the pressure is applied, applying a stimulus to the artery, determining, over one or more cardiac cycles, a stimulus-affected value for the parameter related to the cross-sectional area of the artery, while the pressure is applied and while the artery is in a dilated state affected by the stimulus and evaluating the artery based on a comparison of the determined stimulus-affected and baseline values, the baseline value is determined while the artery is substantially not affected by the stimulus.
Owner:DAFNI EHUD

Arterial obstruction treatment kit

A kit for performing angioplasty or stenting in a blood vessel, composed of at least two components. One of the components includes a first catheter providing a blood bypass flow path and carrying a blocking balloon and a blood vessel dilation device. Another one of the components includes a second catheter having an imperforate wall enclosing an axial lumen and having an open distal end, a hollow tube surrounding, and movable longitudinally with respect to, the second catheter, and a second blocking balloon carried by the hollow tube.
Owner:DON MICHAEL INT +1

Vasodilator-enhanced cardiopulmonary resuscitation

InactiveUS20120203147A1Increase blood flowImprove artificial circulationBiocideHeavy metal active ingredientsImpedance threshold deviceVascular dilatation
A method for increasing blood flow to vital organs during cardiopulmonary resuscitation of a person experiencing a cardiac arrest may include performing standard or active compression decompression cardiopulmonary resuscitation on a person to create artificial circulation by repetitively compressing the person's chest such that the person's chest is subject to a compression phase and a relaxation or decompression phase. The method may also include administering one or more vasodilator drugs to the person to improve the artificial circulation created by the cardiopulmonary resuscitation. The method may also include binding at least a portion of the person's abdomen, either manually or with an abdominal compression device. Performing cardiopulmonary resuscitation on a person may include ventilating the person with either an impedance threshold device or a intrathoracic pressure regulator.
Owner:ZOLL MEDICAL CORPORATION

Inhalable formulations for treating pulmonary hypertension and methods of using same

The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
Owner:DEY

Method for protecting humans against superficial vasodilator flush syndrome,

Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic acid, vitamin B12 and a serotonin inhibitor. Such treatment prevents, reduces or eliminates SVFS in patients receiving as much as 300-3000 mg / day of niacin therapeutically, whether administered prior to, or along with, an anti-SVFS composition.
Owner:THETA BIOMEDICAL CONSULTING & DEVMENT

Transdermal anesthetic and vasodilator composition and methods for topical administration

A composition for topical application comprising a therapeutically effective amount of a topical anesthetic, a safe and effective amount of a pharmaceutically acceptable topical vasodilator and a pharmaceutically acceptable carrier and a method of administering the composition to a mammal are disclosed.
Owner:SAMUELS PAUL J +1

Regulation of cerebral blood flow by temperature change-induced vasodilatation

A method for enhancing cerebral blood flow in a patient. The patient's baseline cerebral blood flow is measured. An artery of the patient is cooled or warmed to produce vasodilatation of the artery. The artery is typically one or more of the left or right common carotid artery, left or right internal carotid artery, left or right middle cerebral artery, anterior cerebral artery, left or right vertebral artery, or basilar artery. Vasodilatation enhances cerebral blood flow. The enhanced cerebral blood flow is measured after cooling or warming the artery. The enhanced cerebral blood flow is compared to the baseline cerebral blood flow. Cooling or warming is then adjusted as needed to achieve a desired enhancement in cerebral blood flow. Devices for cooling and warming are also described.
Owner:ZOLL CIRCULATION

Embolic protection apparatus with vasodilator coating

An apparatus for temporary prevention of embolization in a human blood vessel. The apparatus comprises a body that is transformable between a radially collapsed configuration and a radially expanded configuration sized and shaped for sealing against an inner wall of the vessel to at least partially obstruct fluid flowing there through, the body having a vasodilator coating.
Owner:MEDTRONIC VASCULAR INC

Purine nucleotide analogues, pharmaceutical compositions thereof, and methods of improving cardiac functions

The specification discloses purine nucleotide analogues which modulate cardiac muscle contractility and possess vasodilator activity. In addition, related methods of administration and the identity of receptors that bind these compounds are disclosed.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Composition for protection against superficial vasodilator flush syndrome

InactiveUS20050220909A1Promote absorptionBiocideCosmetic preparationsChondroitin Sulfate CVascular dilatation
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biomolecules from the activated mast cells, composed of a heavily sulfated, non-bovine proteoglycan such as shark cartilage chondroitin sulfate C, an unrefined olive kernel oil / extract that increases absorption of these compositions in various routes of administration, and one or more of a hexosamine sulfate such as D-glucosamine sulfate, a flavone such as quercetin, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRH, caffeine, and a polyamine.
Owner:THEOHARIDES THEOHARIS C

Enhanced delivery of cells

The present invention provides a method comprising administering cells by infusion through a blood vessel and administering a vasodilator, a vascular enhancer, or both. In accordance with one embodiment, the delivery of stem cells to the myocardium by intracoronary infusion is improved by administration of one or more vasodilators and / or vascular permeability enhancers prior to or at the time of cell therapy.
Owner:BOSTON SCI SCIMED INC

Supplemented and unsupplemented tissue sealants, methods of their production and use

This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation inhibiting composition. The composition may be further supplemented with, for example, one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like.
Owner:AMERICAN NAT RED CROSS

Administration of capsaicinoids

Disclosed in certain embodiments is a method for relieving pain at a site in a human or animal in need thereof, comprising administering by injection or infiltration, a dose of a capsaicinoid and coadministering a vasodilator.
Owner:ALGORX PHARMA INC

Vasodilator cannabinoid analogs

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes the cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotuctants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3
Owner:VIRGINIA COMMONWEALTH UNIV

Supplemented and unsupplemented tissue sealants, methods of their production and use

This invention provides methods for the localized delivery of supplemented tissue sealants, wherein the supplemented tissue sealants comprise at least one composition which is selected from one or more antibodies, analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, antiproliferatives, cytokines, cytotoxins, drugs, growth factors, interferons, hormones, lipids, demineralized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors or vasodilators, vitamins, minerals, stabilizers and the like. Further provided are methods of using the site-specific supplemented tissue sealants, including preparation of a biomaterial.
Owner:AMERICAN NAT RED CROSS

Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof

The invention relates to a new pharmacotherapeutical strategy, to an anti-stress, anti-impairment and anti-aging drug and to a process for its manufacturing. The drug has an etio-pathogenic and homeostatic action, was preclinically tested and clinically checked up in geriatric, neurologic, psychiatric and stress-dependent pathology. The drug achieves a synergistic biological, neurometabolic and cell-trophic composition, being elaborated by the association of the following active principles: a) against oxidative and catabolic stress; methionine with aminoethanol phenoxyacetates and / or aminoethyl phenoxyacetamides; b) against anabolic stress; hydroxopyrimidine carboxylates and / or oxopyrrolidine acetamides with potassium, zinc and lithium; c) vasodilative and normolipidemic; nicotinic, alcohol and / or acid, or its derivatives, with magnesium and iodine; d) energo-active and e) anti-toxic; aspartate; fructose; vitamin B1; vitamin B6; monoacid phosphate and sulfate. The process for manufacturing the drug stipulates; a) pharmaceutical preparation in two complementary types of capsules or coated tablets, gastrosoluble and enterosoluble, the last being enteric coated; b) prolonged-release of vasodilator from the enterosoluble unit.
Owner:RIGA DAN +1

Cosmetic herbal compositions

Herbal cosmetic skin care compositions formulated to combat conditions associated with oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an herbal agent derived from one or more of the plant species, as well as cosmetically acceptable carriers. Other agents that may be included are proteins, peptides, anti-inflammatory agents, and / or vasodilators. These cosmetic compositions find use in improving the appearance of aged or damaged skin.
Owner:JAN MARINI SKIN RES

Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.
Owner:ASAHI KASEI PHARMA

Drug delivery device and method for bi-directional drug delivery

A drug delivery device is provided with openings for directional delivery of a plurality of therapeutic agents to blood vessels or other lumens or organs. In particular, the invention relates to the delivery of different therapeutic agents, different quantities of therapeutic agents, or different release profiles of the same or different therapeutic agents in different directions from the drug delivery device. The invention is useful, for example, for delivering antirestenotic, antithrombotic, antiplatelet, antiproliferative, antineoplastic, immunosuppressive, angiogenic, anti-inflammatory, or antiangiogenic agents and / or vasodilators to a blood vessel. In one embodiment, antiproliferative, antineoplastic, angiogenic, antiangiogenic, anti-inflammatory, and / or antirestenotic agents are delivered to the wall of a blood vessel and antithrombotic agents, antiplatelet agents, and / or vasodilators are delivered to the lumen of a blood vessel.
Owner:MICROPORT CARDIOVASCULAR LLC

Transdermal drug delivery formulations with optimal amounts of vasodilators therein

Topical drug delivery formulations with optical amounts of vasodilator. Vasodilator chemicals applied topically dilate the blood vessels in the skin tissue, which have been shown to facilitate or inhibit systemic or skin tissue deposition of drug substances. The level of stimulation and / or inhibition has been found to be dependent on the concentration and the identity of the specific vasodilator chemical(s) used as well as the drug molecule(s) to be delivered. This work teaches the need to consider specific formulation requirements when dealing with vasodilator chemicals for the creation of successful delivery vehicles in the transdermal drug delivery system. These requirements for very low concentrations of vasodilators were an unexpected and a surprise finding, in contrast to the concentrations of the vasodilators typically used to elicit an increase in skin blood flow.
Owner:BIOCHEMICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products